{"id":44359,"date":"2022-05-26T00:01:28","date_gmt":"2022-05-25T22:01:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/"},"modified":"2022-05-26T00:01:28","modified_gmt":"2022-05-25T22:01:28","slug":"rapid-dose-therapeutics-closes-first-tranche-of-private-placement","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/","title":{"rendered":"Rapid Dose Therapeutics Closes First Tranche of Private Placement"},"content":{"rendered":"
\n

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (\u201cRDT\u201d<\/b>), (CSE: DOSE)<\/b>, a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is pleased to announce the closing of the first tranche of a Private Placement.\n<\/p>\n

<\/a><\/p>\n

\nThe tranche consists of 506,157 Common Share Units at a price of $0.30 per Unit for net proceeds to the Company of $151,847. Each Unit consists of one Common Share and one Common Share Purchase Warrant which entitles the holder to acquire one Common Share of the Company at $0.40 per Share. The Share Purchase Warrants expire twenty\u2010four months from the date of issuance.\n<\/p>\n

\nThe funds will be used by the Company to continue the commercialization of its proprietary drug delivery technologies and for general corporate purposes.\n<\/p>\n

\nAbout Rapid Dose Therapeutics Corp.<\/b>\n<\/p>\n

\nRapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company\u2019s flagship product QuickStrip\u2122 is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.
\n
www.rapid-dose.com<\/a>\n<\/p>\n

\nCAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:\n<\/p>\n

\nCertain information in this news release may contain forward-looking information within the meaning of applicable securities laws.<\/i> Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpect\u201d, \u201cpotential\u201d, \u201cbelieve\u201d, \u201cintend\u201d, \u201cwill\u201d, \u201ccould\u201d, \u201care planned to\u201d, \u201care expected to\u201d or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip\u2122 product delivery method, the generation of recurring revenues, as at the date of this news release, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and\/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nRDT Investors:<\/b>
Mark Upsdell, CEO
\n
mupsdell@rapid-dose.com<\/a>
416-477-1052\n<\/p>\n

\nMedia:<\/b>
Dara Willis
\n
dara@dwcomm.ca<\/a>
416-836-9272\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (\u201cRDT\u201d), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is pleased to announce the closing of the first tranche of a Private Placement. The tranche consists of 506,157 Common Share Units at a price of $0.30 per Unit for net proceeds to the Company … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-44359","6":"format-standard","7":"category-industry"},"yoast_head":"\nRapid Dose Therapeutics Closes First Tranche of Private Placement - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rapid Dose Therapeutics Closes First Tranche of Private Placement - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (\u201cRDT\u201d), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is pleased to announce the closing of the first tranche of a Private Placement. The tranche consists of 506,157 Common Share Units at a price of $0.30 per Unit for net proceeds to the Company ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T22:01:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220525005928\/en\/1204121\/21\/RDT_LOGO.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Rapid Dose Therapeutics Closes First Tranche of Private Placement\",\"datePublished\":\"2022-05-25T22:01:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/\"},\"wordCount\":532,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005928\\\/en\\\/1204121\\\/21\\\/RDT_LOGO.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/\",\"name\":\"Rapid Dose Therapeutics Closes First Tranche of Private Placement - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005928\\\/en\\\/1204121\\\/21\\\/RDT_LOGO.jpg\",\"datePublished\":\"2022-05-25T22:01:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005928\\\/en\\\/1204121\\\/21\\\/RDT_LOGO.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220525005928\\\/en\\\/1204121\\\/21\\\/RDT_LOGO.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rapid Dose Therapeutics Closes First Tranche of Private Placement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rapid Dose Therapeutics Closes First Tranche of Private Placement - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/","og_locale":"en_US","og_type":"article","og_title":"Rapid Dose Therapeutics Closes First Tranche of Private Placement - Pharma Trend","og_description":"BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (\u201cRDT\u201d), (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is pleased to announce the closing of the first tranche of a Private Placement. The tranche consists of 506,157 Common Share Units at a price of $0.30 per Unit for net proceeds to the Company ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/","og_site_name":"Pharma Trend","article_published_time":"2022-05-25T22:01:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220525005928\/en\/1204121\/21\/RDT_LOGO.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Rapid Dose Therapeutics Closes First Tranche of Private Placement","datePublished":"2022-05-25T22:01:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/"},"wordCount":532,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005928\/en\/1204121\/21\/RDT_LOGO.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/","url":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/","name":"Rapid Dose Therapeutics Closes First Tranche of Private Placement - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220525005928\/en\/1204121\/21\/RDT_LOGO.jpg","datePublished":"2022-05-25T22:01:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220525005928\/en\/1204121\/21\/RDT_LOGO.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220525005928\/en\/1204121\/21\/RDT_LOGO.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/rapid-dose-therapeutics-closes-first-tranche-of-private-placement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Rapid Dose Therapeutics Closes First Tranche of Private Placement"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=44359"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/44359\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=44359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=44359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=44359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}